ArticleCancer immunology, immunotherapy : CII2022

Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.

Jutatip Panaampon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.